sorafenib has been researched along with Cells, Neoplasm Circulating in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 13 (61.90) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Hsieh, CH; Huang, YH; Lai, MW; Yeh, CT | 1 |
| Cao, B; Da, X; Fan, M; Huang, J; Li, Q; Lu, H; Lu, L; Lu, Y; Mo, J | 1 |
| Liu, M; Mou, T; Shen, A; Shi, J; Wang, Y; Wu, Z | 1 |
| Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kimura, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nagata, Y; Nakahara, T; Nishida, Y; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S | 1 |
| Ebert, MP; Schlitt, HJ; Sollors, J; Steinebrunner, N; Stroszczynski, C; Teufel, A; Weiss, KH; Zhan, T | 1 |
| Benson, AB; Bergsland, EK; Grabowsky, JA; Huang, Y; Hwang, J; Kelley, RK; Ko, AH; Korn, WM; Kuhn, P; Li, CM; Luttgen, MS; Mulcahy, MF; Munster, PN; Nimeiri, HS; Stucky-Marshall, L; Venook, AP; Vergo, MT; Yeh, BM | 1 |
| Chai, ZT; Gao, DM; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xu, HX; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
| Anderson, SK; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Kimlinger, TK; Kumar, SK; Lafky, JM; Northfelt, DW; Uhm, JH | 1 |
| Garcia-Donas, J; Jonasch, E; Rodriguez-Antona, C | 1 |
| Ahn, H; Hong, JH; Jeong, IG; Kim, CS; Kwon, T; Lee, JL; Song, C; You, D | 1 |
| Chiba, T; Kanogawa, N; Kobayashi, K; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O | 1 |
| Labgaa, I; Villanueva, A | 1 |
| Chen, L; Ge, N; Li, J; Liu, H; Qian, H; Shi, L; Sun, B; Wu, M; Yang, X; Yang, Y; Yin, Z; Zhang, X | 1 |
| Bai, T; Chen, J; Chen, JZ; Li, LQ; Lu, Z; Ma, L; Peng, YC; Qin, HG; Xiang, BD; Xie, ZB; Ye, HH; Ye, JZ | 1 |
| Andrea, A; Di Silverio, F; Panebianco, V; Parente, U; Passariello, R; Sciarra, A; Von Heland, M | 1 |
| Hakenberg, OW | 1 |
| Shibuya, M | 1 |
| Barbaro, B; Gasbarrini, A; Lauritano, EC; Novi, M; Piscaglia, AC; Pompili, M; Zocco, MA | 1 |
| Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Nakatake, R; Yanagimoto, Y | 1 |
| Barbero, C; Campisi, P; Centofanti, P; Giorgi, M; Molino, F; Rinaldi, M; Salizzoni, S | 1 |
| Andreeff, M; Cortes, J; Estrov, Z; Harris, D; Konopleva, M; Ling, X; McQueen, T; Quintás-Cardama, A; Shi, YX; Small, D; Zhang, W | 1 |
5 review(s) available for sorafenib and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Neoplasm Staging; Neoplastic Cells, Circulating; Portal Vein; Prognosis; Safety; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis | 2020 |
Pharmacological treatment of hepatocellular carcinoma with cavoatrial tumor thrombus - case series and literature review.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fatal Outcome; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Sorafenib; Thrombosis; Vena Cava, Inferior; Venous Thrombosis | 2019 |
Molecular markers to predict response to therapy.
Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Bevacizumab; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Gene Dosage; Humans; Immunotherapy; Indazoles; Indoles; Kidney Neoplasms; Mutation; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Polymorphism, Genetic; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Von Hippel-Lindau Tumor Suppressor Protein | 2013 |
Liquid biopsy in liver cancer.
Topics: Alleles; Biomarkers, Tumor; Biopsy; Carcinoma, Hepatocellular; Clinical Trials as Topic; DNA, Neoplasm; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2015 |
Angiogenesis regulated by VEGF and its receptors and its clinical application.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Design; Humans; Indoles; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
3 trial(s) available for sorafenib and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Protein Precursors; Prothrombin; Sirolimus; Sorafenib; Treatment Outcome | 2013 |
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Proportional Hazards Models; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Cell Survival; Fluorescent Antibody Technique; fms-Like Tyrosine Kinase 3; Humans; Immunoblotting; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Mutation; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyridines; Sorafenib; Transplantation, Heterologous | 2008 |
13 other study(ies) available for sorafenib and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Circulating Tumor Cells Derived from Advanced Hepatocellular Carcinoma Rapidly Develop Resistance to Cytotoxic Chemotherapy.
Topics: Carcinoma, Hepatocellular; Cell Count; Humans; Liver Neoplasms; Neoplastic Cells, Circulating; Sorafenib | 2022 |
Targeted co-delivery of PD-L1 monoclonal antibody and sorafenib to circulating tumor cells via platelet-functionalized nanocarriers.
Topics: Animals; Antibodies, Monoclonal; B7-H1 Antigen; Blood Platelets; Cell Line, Tumor; Mice; Nanoparticles; Neoplastic Cells, Circulating; Sorafenib; Tissue Distribution | 2023 |
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Interferons; Liver Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Portal Vein; Radiotherapy, Conformal; Retrospective Studies; Sorafenib; Survival Rate | 2018 |
Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendritic Cells; Diphosphonates; Heterografts; Humans; Imidazoles; Immunosuppression Therapy; Indoles; Interleukin-12 Subunit p40; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasm Transplantation; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Zoledronic Acid | 2013 |
Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombectomy; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2014 |
Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Necrosis; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Portal Vein; Regional Blood Flow; Sorafenib; Vascular Access Devices | 2015 |
pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; Fluorescent Antibody Technique; Follow-Up Studies; Humans; Immunoenzyme Techniques; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Phosphorylation; Prognosis; Proto-Oncogene Proteins c-akt; Sorafenib; Survival Rate; Tumor Cells, Cultured | 2016 |
Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Chi-Square Distribution; Female; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Niacinamide; Odds Ratio; Phenylurea Compounds; Portal Vein; Proportional Hazards Models; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Venous Thrombosis | 2016 |
Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Risk Assessment; Sorafenib; Treatment Outcome; Vena Cava, Inferior | 2008 |
Comment on Di Silverio et al.: Neodajuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int 2008;80:451-453.
Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Treatment Outcome; Vena Cava, Inferior | 2008 |
Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma.
Topics: Angiography; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Risk Assessment; Sorafenib; Treatment Outcome | 2009 |
[The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cisplatin; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Pilot Projects; Portal Vein; Pyridines; Sorafenib; Venous Thrombosis | 2010 |
Right sided heart mass reveals hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Male; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Sorafenib; Thrombosis | 2012 |